BeOne’s next-generation BCL2 inhibitor sonrotoclax (branded Beqalzi) received FDA accelerated approval in mantle cell lymphoma following treatment with a BTK inhibitor. The label creates a new US therapeutic anchor for patients who have progressed on Bruton’s tyrosine kinase–targeted therapies, where response durability has been a persistent challenge. With the approval now in hand, BeOne is expected to shift attention to combination development, particularly with BTK inhibitors already embedded in standard care for MCL. That development direction is likely to shape near-term competitive dynamics for post-BTK treatment lines. For biotech investors and strategic partners, this is another example of how incremental targeted approvals can quickly open follow-on combination pathways in hematology.